Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatomyositis | 29 | 2024 | 256 | 10.760 |
Why?
|
Lupus Erythematosus, Discoid | 12 | 2024 | 61 | 4.270 |
Why?
|
Fasciitis | 7 | 2023 | 67 | 4.230 |
Why?
|
Eosinophilia | 8 | 2023 | 559 | 3.860 |
Why?
|
Connective Tissue Diseases | 6 | 2024 | 286 | 2.490 |
Why?
|
Lupus Erythematosus, Cutaneous | 9 | 2021 | 73 | 2.400 |
Why?
|
Lupus Erythematosus, Systemic | 12 | 2024 | 2159 | 2.050 |
Why?
|
Dermatologic Agents | 10 | 2024 | 307 | 1.990 |
Why?
|
Mycophenolic Acid | 5 | 2022 | 343 | 1.920 |
Why?
|
Raynaud Disease | 4 | 2023 | 79 | 1.820 |
Why?
|
Scleroderma, Systemic | 6 | 2023 | 344 | 1.750 |
Why?
|
Immunoglobulins, Intravenous | 8 | 2023 | 664 | 1.720 |
Why?
|
Skin Diseases | 9 | 2022 | 1089 | 1.660 |
Why?
|
Skin Ulcer | 3 | 2023 | 129 | 1.420 |
Why?
|
Scleroderma, Localized | 5 | 2023 | 87 | 1.400 |
Why?
|
Dermatology | 11 | 2022 | 914 | 1.390 |
Why?
|
Pityriasis Rubra Pilaris | 3 | 2021 | 18 | 1.300 |
Why?
|
Botulinum Toxins, Type A | 2 | 2023 | 229 | 1.280 |
Why?
|
Methotrexate | 12 | 2024 | 1719 | 1.270 |
Why?
|
Hand Dermatoses | 4 | 2016 | 62 | 1.270 |
Why?
|
Exanthema | 4 | 2023 | 504 | 1.240 |
Why?
|
Paraproteinemias | 3 | 2021 | 246 | 1.180 |
Why?
|
Immunosuppressive Agents | 11 | 2022 | 4166 | 1.010 |
Why?
|
Immunologic Factors | 5 | 2021 | 1588 | 0.870 |
Why?
|
Autoantibodies | 5 | 2023 | 2118 | 0.870 |
Why?
|
Psoriasis | 9 | 2024 | 940 | 0.860 |
Why?
|
Pemphigoid, Bullous | 2 | 2015 | 114 | 0.820 |
Why?
|
Panniculitis | 2 | 2012 | 45 | 0.800 |
Why?
|
Calcinosis | 3 | 2018 | 1476 | 0.770 |
Why?
|
Porphyria Cutanea Tarda | 1 | 2021 | 11 | 0.750 |
Why?
|
Autoimmune Diseases | 3 | 2024 | 2250 | 0.730 |
Why?
|
Adrenal Cortex Hormones | 5 | 2021 | 1869 | 0.730 |
Why?
|
Antimalarials | 4 | 2020 | 906 | 0.700 |
Why?
|
Thiosulfates | 2 | 2018 | 53 | 0.700 |
Why?
|
Skin | 10 | 2024 | 4466 | 0.690 |
Why?
|
Insurance | 1 | 2021 | 114 | 0.660 |
Why?
|
Alopecia Areata | 1 | 2021 | 127 | 0.610 |
Why?
|
Foot Dermatoses | 2 | 2016 | 47 | 0.610 |
Why?
|
Anti-Asthmatic Agents | 1 | 2023 | 565 | 0.610 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2019 | 421 | 0.610 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.610 |
Why?
|
Piperidines | 4 | 2021 | 1650 | 0.600 |
Why?
|
Humans | 131 | 2024 | 760621 | 0.580 |
Why?
|
Sunlight | 2 | 2020 | 337 | 0.550 |
Why?
|
Tumor Necrosis Factor-alpha | 7 | 2021 | 4357 | 0.540 |
Why?
|
Skin Diseases, Genetic | 1 | 2016 | 49 | 0.530 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 640 | 0.520 |
Why?
|
Needlestick Injuries | 1 | 2016 | 71 | 0.520 |
Why?
|
Hidradenitis Suppurativa | 2 | 2018 | 173 | 0.520 |
Why?
|
Erythromelalgia | 1 | 2014 | 15 | 0.490 |
Why?
|
Scleredema Adultorum | 1 | 2014 | 2 | 0.490 |
Why?
|
Tetracycline | 1 | 2015 | 220 | 0.480 |
Why?
|
Rosacea | 1 | 2015 | 59 | 0.480 |
Why?
|
Enchondromatosis | 1 | 2014 | 14 | 0.480 |
Why?
|
Administration, Cutaneous | 3 | 2024 | 713 | 0.460 |
Why?
|
Facial Dermatoses | 1 | 2014 | 85 | 0.460 |
Why?
|
Pyrroles | 2 | 2021 | 1137 | 0.460 |
Why?
|
Contracture | 1 | 2016 | 235 | 0.460 |
Why?
|
Urban Health Services | 1 | 2015 | 177 | 0.460 |
Why?
|
Thalidomide | 2 | 2016 | 884 | 0.440 |
Why?
|
Epidermolysis Bullosa Acquisita | 1 | 2013 | 15 | 0.440 |
Why?
|
Subcutaneous Tissue | 2 | 2020 | 132 | 0.440 |
Why?
|
Quality of Life | 7 | 2023 | 13308 | 0.430 |
Why?
|
Scalp Dermatoses | 1 | 2013 | 44 | 0.420 |
Why?
|
Photography | 1 | 2016 | 530 | 0.410 |
Why?
|
Pyrimidines | 4 | 2021 | 3016 | 0.410 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 248 | 0.400 |
Why?
|
Patient Preference | 1 | 2019 | 922 | 0.400 |
Why?
|
Severity of Illness Index | 13 | 2024 | 15840 | 0.400 |
Why?
|
Skin Neoplasms | 6 | 2015 | 5799 | 0.400 |
Why?
|
Chondrosarcoma | 1 | 2014 | 296 | 0.390 |
Why?
|
Facial Hemiatrophy | 2 | 2022 | 24 | 0.380 |
Why?
|
Tacrolimus | 1 | 2015 | 733 | 0.380 |
Why?
|
Skin Diseases, Vascular | 1 | 2011 | 41 | 0.370 |
Why?
|
Female | 66 | 2024 | 391270 | 0.370 |
Why?
|
Retrospective Studies | 30 | 2023 | 80372 | 0.360 |
Why?
|
Treatment Outcome | 22 | 2023 | 65017 | 0.360 |
Why?
|
Middle Aged | 41 | 2024 | 220352 | 0.360 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1864 | 0.350 |
Why?
|
Radiation Injuries | 2 | 2016 | 1183 | 0.350 |
Why?
|
Lymphoma, T-Cell | 1 | 2012 | 305 | 0.340 |
Why?
|
Hydroxychloroquine | 4 | 2020 | 427 | 0.340 |
Why?
|
Calciphylaxis | 1 | 2011 | 130 | 0.330 |
Why?
|
Myositis | 2 | 2023 | 269 | 0.330 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 3025 | 0.330 |
Why?
|
Administration, Oral | 4 | 2020 | 4035 | 0.330 |
Why?
|
Immunity, Cellular | 1 | 2015 | 1557 | 0.320 |
Why?
|
Antirheumatic Agents | 2 | 2020 | 1374 | 0.310 |
Why?
|
Edema | 1 | 2012 | 769 | 0.300 |
Why?
|
Panniculitis, Lupus Erythematosus | 2 | 2020 | 5 | 0.300 |
Why?
|
Health Expenditures | 2 | 2022 | 2362 | 0.300 |
Why?
|
Clinical Clerkship | 1 | 2014 | 563 | 0.300 |
Why?
|
Abdominal Pain | 1 | 2014 | 1063 | 0.290 |
Why?
|
Carcinoma, Basal Cell | 2 | 2014 | 559 | 0.290 |
Why?
|
Academic Medical Centers | 4 | 2021 | 2754 | 0.290 |
Why?
|
Adult | 38 | 2024 | 219994 | 0.290 |
Why?
|
Interferon Type I | 2 | 2024 | 559 | 0.280 |
Why?
|
Male | 47 | 2024 | 359744 | 0.280 |
Why?
|
Salvage Therapy | 1 | 2013 | 1268 | 0.280 |
Why?
|
Sunscreening Agents | 2 | 2020 | 139 | 0.280 |
Why?
|
Alopecia | 3 | 2019 | 414 | 0.270 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2013 | 1096 | 0.270 |
Why?
|
Erythema | 2 | 2020 | 262 | 0.260 |
Why?
|
Diagnosis, Differential | 7 | 2021 | 12965 | 0.260 |
Why?
|
Sarcoidosis | 2 | 2021 | 520 | 0.250 |
Why?
|
Education, Medical, Undergraduate | 1 | 2014 | 1066 | 0.240 |
Why?
|
Chemokine CXCL13 | 1 | 2024 | 59 | 0.230 |
Why?
|
Microstomia | 1 | 2023 | 11 | 0.230 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2023 | 32 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2024 | 285 | 0.220 |
Why?
|
Drug Eruptions | 2 | 2019 | 335 | 0.220 |
Why?
|
Drug Therapy, Combination | 4 | 2020 | 6498 | 0.220 |
Why?
|
Keloid | 1 | 2023 | 54 | 0.220 |
Why?
|
Cutis Laxa | 1 | 2023 | 29 | 0.210 |
Why?
|
Antibodies, Monoclonal | 4 | 2015 | 9185 | 0.210 |
Why?
|
Internship and Residency | 3 | 2021 | 5870 | 0.210 |
Why?
|
Cicatrix, Hypertrophic | 1 | 2023 | 81 | 0.210 |
Why?
|
Dermatitis, Atopic | 2 | 2023 | 716 | 0.200 |
Why?
|
Immunoglobulin G | 2 | 2013 | 4541 | 0.200 |
Why?
|
Aged | 23 | 2024 | 169152 | 0.200 |
Why?
|
Ultraviolet Rays | 2 | 2020 | 1078 | 0.200 |
Why?
|
Grasshoppers | 3 | 2010 | 20 | 0.200 |
Why?
|
Delayed Diagnosis | 3 | 2020 | 464 | 0.200 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2024 | 220 | 0.200 |
Why?
|
Telemedicine | 2 | 2020 | 3018 | 0.200 |
Why?
|
Curriculum | 2 | 2020 | 3718 | 0.190 |
Why?
|
Biopsy | 5 | 2020 | 6771 | 0.190 |
Why?
|
Biopsy, Needle | 3 | 2016 | 1630 | 0.190 |
Why?
|
Chilblains | 1 | 2021 | 16 | 0.190 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2021 | 22 | 0.190 |
Why?
|
Infusions, Intravenous | 2 | 2018 | 2234 | 0.190 |
Why?
|
Antipruritics | 1 | 2020 | 31 | 0.180 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2943 | 0.180 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 10 | 0.180 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21025 | 0.170 |
Why?
|
Protective Clothing | 1 | 2020 | 103 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5643 | 0.170 |
Why?
|
Acne Vulgaris | 3 | 2024 | 355 | 0.170 |
Why?
|
Face | 3 | 2020 | 1017 | 0.170 |
Why?
|
Necrobiosis Lipoidica | 1 | 2019 | 14 | 0.170 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2019 | 17 | 0.170 |
Why?
|
Early Diagnosis | 2 | 2021 | 1180 | 0.160 |
Why?
|
Biological Factors | 1 | 2020 | 157 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 4 | 2013 | 1796 | 0.160 |
Why?
|
Cough | 2 | 2019 | 595 | 0.160 |
Why?
|
Dapsone | 2 | 2016 | 56 | 0.160 |
Why?
|
Brachytherapy | 2 | 2017 | 1238 | 0.160 |
Why?
|
Necrosis | 1 | 2023 | 1612 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13262 | 0.150 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1139 | 0.150 |
Why?
|
Patient Care Management | 1 | 2021 | 303 | 0.150 |
Why?
|
Pilot Projects | 4 | 2020 | 8555 | 0.150 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2018 | 169 | 0.150 |
Why?
|
Sampling Studies | 2 | 2016 | 613 | 0.150 |
Why?
|
Follow-Up Studies | 7 | 2017 | 39261 | 0.150 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2882 | 0.150 |
Why?
|
Algorithms | 2 | 2016 | 13981 | 0.150 |
Why?
|
Adolescent | 14 | 2024 | 87810 | 0.150 |
Why?
|
Immunohistochemistry | 4 | 2016 | 11071 | 0.150 |
Why?
|
Chloroquine | 1 | 2019 | 277 | 0.150 |
Why?
|
Acrodermatitis | 1 | 2017 | 15 | 0.150 |
Why?
|
Risk Assessment | 5 | 2023 | 24123 | 0.140 |
Why?
|
Self-Help Groups | 1 | 2019 | 189 | 0.140 |
Why?
|
Comorbidity | 4 | 2021 | 10551 | 0.140 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5397 | 0.140 |
Why?
|
Cohort Studies | 11 | 2024 | 41335 | 0.140 |
Why?
|
Administration, Topical | 1 | 2019 | 697 | 0.140 |
Why?
|
Vasculitis | 1 | 2021 | 523 | 0.140 |
Why?
|
Antioxidants | 2 | 2018 | 1667 | 0.140 |
Why?
|
Melanoma | 2 | 2015 | 5697 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4899 | 0.140 |
Why?
|
Education, Distance | 1 | 2020 | 258 | 0.140 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7408 | 0.140 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 25942 | 0.140 |
Why?
|
Lung Diseases, Interstitial | 2 | 2022 | 911 | 0.130 |
Why?
|
Chelating Agents | 1 | 2018 | 384 | 0.130 |
Why?
|
Erythema Nodosum | 1 | 2016 | 31 | 0.130 |
Why?
|
Diagnostic Self Evaluation | 1 | 2018 | 225 | 0.130 |
Why?
|
Arthritis | 1 | 2021 | 666 | 0.130 |
Why?
|
Th17 Cells | 1 | 2022 | 787 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 934 | 0.130 |
Why?
|
Drug Resistance, Multiple | 1 | 2016 | 254 | 0.120 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 4878 | 0.120 |
Why?
|
Interferon-beta | 1 | 2017 | 345 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1832 | 0.120 |
Why?
|
Dyspnea | 2 | 2019 | 1352 | 0.120 |
Why?
|
Arthralgia | 1 | 2019 | 461 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1392 | 0.120 |
Why?
|
Hypothyroidism | 1 | 2019 | 665 | 0.120 |
Why?
|
Retreatment | 1 | 2016 | 600 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6315 | 0.120 |
Why?
|
Blister | 1 | 2015 | 86 | 0.120 |
Why?
|
Child | 13 | 2024 | 79806 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 1599 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2013 | 585 | 0.120 |
Why?
|
Stroke | 1 | 2016 | 9962 | 0.110 |
Why?
|
Lichen Planus | 1 | 2014 | 71 | 0.110 |
Why?
|
Internal Medicine | 1 | 2021 | 1048 | 0.110 |
Why?
|
Drug Approval | 1 | 2021 | 816 | 0.110 |
Why?
|
Light | 1 | 2019 | 1344 | 0.110 |
Why?
|
Nails, Malformed | 1 | 2013 | 34 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2852 | 0.110 |
Why?
|
Medically Underserved Area | 1 | 2015 | 257 | 0.100 |
Why?
|
Drug Labeling | 1 | 2015 | 251 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10827 | 0.100 |
Why?
|
Pemphigus | 1 | 2013 | 116 | 0.100 |
Why?
|
Paresthesia | 1 | 2013 | 162 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1249 | 0.100 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2010 | 1245 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 175 | 0.100 |
Why?
|
Sex Factors | 4 | 2021 | 10547 | 0.100 |
Why?
|
International Cooperation | 1 | 2018 | 1433 | 0.100 |
Why?
|
United States | 8 | 2023 | 72461 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2024 | 4353 | 0.100 |
Why?
|
Physicians, Women | 1 | 2017 | 495 | 0.100 |
Why?
|
Prednisone | 2 | 2013 | 1565 | 0.100 |
Why?
|
Young Adult | 10 | 2024 | 58741 | 0.100 |
Why?
|
Vitellogenesis | 1 | 2010 | 3 | 0.090 |
Why?
|
Arm | 1 | 2014 | 583 | 0.090 |
Why?
|
Insect Hormones | 1 | 2010 | 73 | 0.090 |
Why?
|
Tyramine | 1 | 2010 | 53 | 0.090 |
Why?
|
Octopamine | 1 | 2010 | 43 | 0.090 |
Why?
|
Receptors, Biogenic Amine | 1 | 2010 | 4 | 0.090 |
Why?
|
Naphthalenes | 1 | 2011 | 198 | 0.090 |
Why?
|
Parotid Neoplasms | 1 | 2012 | 157 | 0.090 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4291 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2932 | 0.090 |
Why?
|
Nephrology | 1 | 2014 | 263 | 0.090 |
Why?
|
Hyaluronic Acid | 1 | 2013 | 482 | 0.090 |
Why?
|
DNA, Mitochondrial | 2 | 2006 | 858 | 0.090 |
Why?
|
Medicine | 1 | 2018 | 943 | 0.080 |
Why?
|
Occupational Health | 1 | 2016 | 805 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 241 | 0.080 |
Why?
|
Life Cycle Stages | 1 | 2010 | 160 | 0.080 |
Why?
|
Tryptases | 1 | 2010 | 176 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2017 | 1192 | 0.080 |
Why?
|
Disease Progression | 3 | 2023 | 13502 | 0.080 |
Why?
|
Incidence | 3 | 2016 | 21392 | 0.080 |
Why?
|
Mastocytosis, Systemic | 1 | 2010 | 102 | 0.080 |
Why?
|
Cicatrix | 1 | 2014 | 782 | 0.080 |
Why?
|
Education, Medical | 1 | 2020 | 1727 | 0.080 |
Why?
|
Anti-Infective Agents | 1 | 2016 | 981 | 0.080 |
Why?
|
Lactic Acid | 1 | 2013 | 1134 | 0.080 |
Why?
|
Reference Values | 1 | 2015 | 4925 | 0.080 |
Why?
|
Physicians, Primary Care | 1 | 2015 | 624 | 0.080 |
Why?
|
Consensus | 3 | 2024 | 3113 | 0.080 |
Why?
|
Leadership | 1 | 2017 | 1371 | 0.080 |
Why?
|
Faculty | 2 | 2022 | 383 | 0.080 |
Why?
|
Cost of Illness | 1 | 2018 | 1940 | 0.070 |
Why?
|
Rheumatology | 1 | 2014 | 611 | 0.070 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1583 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1617 | 0.070 |
Why?
|
Lung | 3 | 2022 | 9994 | 0.070 |
Why?
|
Prognosis | 3 | 2019 | 29658 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20509 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1266 | 0.070 |
Why?
|
Piperazines | 1 | 2018 | 2525 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2023 | 22053 | 0.070 |
Why?
|
Muscle, Skeletal | 2 | 2020 | 4925 | 0.070 |
Why?
|
Diphosphonates | 1 | 2011 | 638 | 0.070 |
Why?
|
Pain | 1 | 2021 | 5066 | 0.070 |
Why?
|
Polymers | 1 | 2013 | 1621 | 0.070 |
Why?
|
Biological Products | 1 | 2015 | 916 | 0.070 |
Why?
|
Neurotransmitter Agents | 1 | 2010 | 663 | 0.070 |
Why?
|
Body Mass Index | 2 | 2015 | 12914 | 0.070 |
Why?
|
Pyridines | 1 | 2018 | 2879 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7806 | 0.060 |
Why?
|
Data Collection | 1 | 2015 | 3315 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36290 | 0.060 |
Why?
|
Neuropeptides | 1 | 2010 | 943 | 0.060 |
Why?
|
Breast | 1 | 2013 | 1963 | 0.060 |
Why?
|
Skin Aging | 1 | 2006 | 141 | 0.060 |
Why?
|
Philadelphia | 1 | 2024 | 265 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2363 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9716 | 0.060 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2023 | 135 | 0.060 |
Why?
|
Photogrammetry | 1 | 2023 | 77 | 0.060 |
Why?
|
Neoplasms | 2 | 2023 | 22072 | 0.050 |
Why?
|
Recurrence | 2 | 2013 | 8482 | 0.050 |
Why?
|
Diarrhea | 1 | 2010 | 1319 | 0.050 |
Why?
|
Acute Disease | 1 | 2014 | 7269 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58995 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2023 | 278 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9280 | 0.050 |
Why?
|
Cardiology | 1 | 2014 | 1723 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6786 | 0.050 |
Why?
|
Phylogeny | 1 | 2010 | 2775 | 0.050 |
Why?
|
Dermatitis | 1 | 2024 | 200 | 0.050 |
Why?
|
Radiography, Panoramic | 1 | 2022 | 118 | 0.050 |
Why?
|
RNA Interference | 1 | 2010 | 2846 | 0.050 |
Why?
|
Ointments | 1 | 2021 | 58 | 0.050 |
Why?
|
Sequence Deletion | 1 | 2006 | 1493 | 0.050 |
Why?
|
Child, Preschool | 5 | 2024 | 42063 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3865 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 2418 | 0.050 |
Why?
|
Isotretinoin | 1 | 2022 | 131 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3763 | 0.050 |
Why?
|
Publication Bias | 1 | 2021 | 162 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14660 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5889 | 0.040 |
Why?
|
Mutation | 3 | 2021 | 29932 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 412 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 791 | 0.040 |
Why?
|
Prevalence | 2 | 2014 | 15687 | 0.040 |
Why?
|
Risk Factors | 3 | 2023 | 74359 | 0.040 |
Why?
|
Facial Muscles | 1 | 2020 | 159 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2021 | 344 | 0.040 |
Why?
|
Genetic Markers | 1 | 2006 | 2608 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2021 | 691 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8469 | 0.040 |
Why?
|
Withholding Treatment | 2 | 2013 | 613 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2014 | 4412 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9287 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2024 | 975 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 936 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2021 | 279 | 0.040 |
Why?
|
Clinical Competence | 1 | 2014 | 4783 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 8035 | 0.040 |
Why?
|
Back | 1 | 2018 | 64 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1155 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2022 | 471 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 705 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2015 | 10181 | 0.040 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 832 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12922 | 0.030 |
Why?
|
Infant | 2 | 2020 | 36060 | 0.030 |
Why?
|
PUVA Therapy | 1 | 2016 | 101 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6465 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15289 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2017 | 316 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.030 |
Why?
|
Schools, Medical | 1 | 2022 | 878 | 0.030 |
Why?
|
Deglutition Disorders | 1 | 2021 | 626 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2017 | 881 | 0.030 |
Why?
|
Delphi Technique | 1 | 2018 | 829 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13630 | 0.030 |
Why?
|
Thorax | 1 | 2018 | 553 | 0.030 |
Why?
|
North America | 1 | 2017 | 1284 | 0.030 |
Why?
|
Depression | 2 | 2023 | 8044 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9276 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2295 | 0.030 |
Why?
|
Income | 1 | 2022 | 1875 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2893 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4573 | 0.030 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2013 | 85 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9411 | 0.030 |
Why?
|
Urticaria | 1 | 2013 | 150 | 0.030 |
Why?
|
Students | 1 | 2022 | 1730 | 0.020 |
Why?
|
Polyesters | 1 | 2013 | 372 | 0.020 |
Why?
|
Extremities | 1 | 2017 | 867 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 2963 | 0.020 |
Why?
|
Mitochondria | 1 | 2004 | 3600 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11712 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2019 | 895 | 0.020 |
Why?
|
Citalopram | 1 | 2013 | 402 | 0.020 |
Why?
|
Folic Acid | 1 | 2017 | 1309 | 0.020 |
Why?
|
Europe | 1 | 2017 | 3441 | 0.020 |
Why?
|
Ranitidine | 1 | 2010 | 34 | 0.020 |
Why?
|
Flushing | 1 | 2010 | 52 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 693 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4048 | 0.020 |
Why?
|
Cromolyn Sodium | 1 | 2010 | 77 | 0.020 |
Why?
|
Leukotriene Antagonists | 1 | 2010 | 123 | 0.020 |
Why?
|
Behcet Syndrome | 1 | 2010 | 86 | 0.020 |
Why?
|
Radiotherapy | 1 | 2016 | 1504 | 0.020 |
Why?
|
Insurance, Health | 1 | 2022 | 2501 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3448 | 0.020 |
Why?
|
Sulfides | 1 | 2010 | 171 | 0.020 |
Why?
|
Staurosporine | 1 | 2010 | 242 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3202 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9631 | 0.020 |
Why?
|
Histamine H2 Antagonists | 1 | 2010 | 167 | 0.020 |
Why?
|
Alcoholism | 1 | 2019 | 1961 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3301 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2010 | 431 | 0.020 |
Why?
|
Acetates | 1 | 2010 | 321 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1627 | 0.020 |
Why?
|
Crohn Disease | 2 | 2011 | 2275 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8803 | 0.020 |
Why?
|
Students, Medical | 1 | 2020 | 1927 | 0.020 |
Why?
|
Plasma Cells | 1 | 2010 | 591 | 0.020 |
Why?
|
Vomiting | 1 | 2010 | 650 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11481 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1677 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54303 | 0.020 |
Why?
|
Species Specificity | 1 | 2010 | 2418 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12808 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 2819 | 0.020 |
Why?
|
Eosinophils | 1 | 2010 | 944 | 0.020 |
Why?
|
Heteroduplex Analysis | 1 | 2004 | 9 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20080 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4642 | 0.020 |
Why?
|
Electrophoresis, Capillary | 1 | 2004 | 63 | 0.020 |
Why?
|
Quinolines | 1 | 2010 | 759 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2010 | 4169 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18416 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2013 | 2145 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2014 | 2062 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9585 | 0.010 |
Why?
|
Central Nervous System | 1 | 2010 | 1334 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5130 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2017 | 12766 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12103 | 0.010 |
Why?
|
Overweight | 1 | 2012 | 2421 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3726 | 0.010 |
Why?
|
Physicians | 1 | 2017 | 4591 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 8594 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4024 | 0.010 |
Why?
|
Animals | 3 | 2010 | 167963 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 12446 | 0.010 |
Why?
|
Genome, Human | 1 | 2004 | 4417 | 0.010 |
Why?
|